Market Cap: $295.56B
Market Cap: $295.56B
Open
$149.90
Prev. Close
$159.45
High
$158.24
Low
$149.90
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD).
Novartis AG trades on the Other OTC under the ticker NVSEF, priced in USD.
Novartis AG has a market capitalisation of $295.56B, based on its latest share price.
NVSEF trades at 30.76 times its trailing 12-month earnings.
Over the past 52 weeks NVSEF has traded between $123.69 and $171.29.
Yes. Novartis AG's dividend yields 2.76% at the current share price, paying out 90% of its earnings.
Highly profitable: keeps 18.1% of revenue as net profit.
The analyst consensus rating for NVSEF is Hold.
Vasant Narasimhan is the CEO of Novartis AG, which is headquartered in Basel.
Generated automatically from reported financial data. General information only, not financial advice.